EXHIBIT 99.1


INTRABIOTICS ANNOUNCES PRELIMINARY RESULTS OF PHASE III CLINICAL TRIAL OF
ISEGANAN IN CHEMOTHERAPY PATIENTS

MOUNTAIN VIEW, Calif., Sept. 27 -- IntraBiotics Pharmaceuticals, Inc. (Nasdaq:
IBPI - News), today announced preliminary results of its 509 patient Phase III
clinical trial of its lead product, iseganan hydrochloride (HCl) oral solution,
in reducing the incidence and severity of ulcerative oral mucositis in patients
undergoing high-dose chemotherapy for the treatment of cancer. These results
indicated that iseganan did not meet its primary endpoint of reducing oral
mucositis.

The study's primary endpoint was the proportion of patients who did not develop
severe oral mucositis (defined as NCI CTC stomatitis Grade 1 or less, meaning
patients did not experience painful lesions of their oral cavity) during
chemotherapy in the iseganan group versus placebo. 43% of patients in the
iseganan arm did not develop severe oral mucositis versus 37% of patients in the
placebo group, a difference that did not reach statistical significance
(p=0.18).

Secondary analyses predefined by the protocol included reduction in pain,
swallowing difficulty, the proportion of patients who developed ulcerative oral
mucositis, narcotic use and the severity of oral mucositis during chemotherapy.
The study's secondary endpoints trended in favor of iseganan, but did not
achieve statistical significance. Iseganan was well tolerated by this group of
cancer patients, corroborating earlier findings of the safety of oral-topical
application of iseganan.

"Clearly we are disappointed that iseganan failed to show a statistically
significant benefit in treating severe oral mucositis in patients receiving high
dose chemotherapy," said Dr. Ernest Mario, Chairman and Chief Executive Officer.
"We chose severe oral mucositis as a primary indication for iseganan because it
represents a huge unmet medical need. Unfortunately, while iseganan appeared to
show some benefit in this patient setting, the benefit was not statistically
significant. As a result, we will cease the pursuit of severe oral mucositis as
an indication for iseganan."

About Iseganan
Iseganan hydrochloride (HCl) oral solution is a potent, broad-spectrum,
fast-acting antibiotic that functions by a novel mechanism of action,
substantially reducing the likelihood of microbial resistance. It is the first
in a new class of antibiotic peptide drugs known as protegrins, which are
naturally-occurring substances found in mammals where they form part of the
first line of defense against invading bacteria and fungi. Iseganan is also in
clinical development for prevention of ventilator-associated pneumonia (VAP) the
most common infection occurring among patients in the intensive care unit.
Iseganan is also being developed as a treatment of respiratory infections
associated with cystic fibrosis. These indications represent substantial
clinical and market opportunities.

About IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. is a biopharmaceutical company focused on
developing and commercializing high-value anti-infectives and oncology
therapeutics. Additional information is available at the Company's web site,
www.intrabiotics.com.

Certain statements in this press release contain forward-looking information and
are subject to risks and uncertainties, such as statements regarding product
development, clinical developments and projections of future expenses. As such,
they are subject to the occurrence of many events outside of IntraBiotics'
control and are subject to various risk factors that could cause IntraBiotics'
results to differ materially from those expressed in any forward-looking
statement. The risk factors include, without limitation, the inherent risks of
product development failure; uncertainty of the timing, cost, extent and results
of clinical trials; risk of delays in conducting clinical trials due to factors
such as slower than expected rate of patient recruitment, additional regulatory
requests, inability to manufacture sufficient quantities of materials used for
clinical trials, difficulties with clinical supplies or unforeseen safety
issues; the company's ability to raise capital through private or public
financings when needed or on favorable terms; regulatory risks, and risks
related to proprietary rights, market acceptance and competition. These risk
factors are more fully described in documents on file with the Securities and
Exchange Commission including, but not limited to, our Annual Report on Form
10-K for the year ended December 31, 2001 and on Form 10-Q, for the quarter
ended June 30, 2002.